__________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________
SCEMBLIX®▼ (asciminib) has once- or twice-daily oral dosing1
Recommended dosage in adult patients with Ph+ CML-CP, previously treated with ≥2 TKIs and without a known T315I mutation.1
SCEMBLIX should be taken at approximately the same time every day.
If a SCEMBLIX dose is missed by more than 12 hours, advise the patient to skip the dose and take the next dose as scheduled.1
SCEMBLIX should be taken twice daily at approximately 12-hour intervals.1
If a SCEMBLIX dose is missed by more than 6 hours, advise the patient to skip the dose and take the next dose as scheduled.1
Patients should avoid food for at least 2 hours before and 1 hour after taking SCEMBLIX.1
SCEMBLIX tablets should be swallowed whole with a glass of water – patients should not break, crush or chew them.1
SCEMBLIX is available as film-coated tablets.
For further information on changing between dosing schedules for the recommended dose of SCEMBLIX, please refer to the Summary of Product Characteristics.1
SCEMBLIX, an opportunity to manage ≥3rd-line patients with a flexible dosing schedule1
For the management of adverse reactions, the SCEMBLIX dose can be reduced based on individual tolerability.
SCEMBLIX should be permanently discontinued in patients unable to tolerate a total daily dose of 40 mg.1
Since there are no data available in patients with moderate or severe hepatic impairment, caution should be exercised in these patients.1
Withholding SCEMBLIX followed by potential dose reductions and/or permanent discontinuations may be required in case of thrombocytopenia and/or neutropenia, asymptomatic amylase and/or lipase elevation and non-haematological Grade ≥3 adverse reactions. Please refer to the Summary of Product Characteristics for the detailed guidance on managing each of these adverse events and on dose modification of SCEMBLIX.1
An unmet need remains for many CML patients on ≥3rd line of therapy2
BID, twice daily; CML, chronic myeloid leukaemia; Ph+ CML-CP, Philadelphia chromosome-positive chronic myeloid leukaemia in chronic phase; QD, once daily; TKI, tyrosine kinase inhibitor.
SCEMBLIX is indicated for the treatment of adult patients with Philadelphia chromosome-positive chronic myeloid leukaemia (Ph + CML) in chronic phase (CP), previously treated with two or more tyrosine kinase inhibitors, and without a known T315I mutation.1
For further information please refer to the Summary of Product Characteristics.
References
- SCEMBLIX (asciminib) Summary of Product Characteristics.
- Bosi GR, et al. Hematol Transfus Cell Ther 2019;41(3):222–228.